Searched for
BIOCON BIOLOGICS DRUG
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...
- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classificationBiocon Biologics' drug substance facility in Bengaluru has been classified as Voluntary Action Indicated (VAI) by the USFDA. This classific...
- Biocon shares climb 1% on partnership with Civica to boost insulin aspart availability in the USBiocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...
- Biocon Biologics' Bengaluru unit classified as voluntary action indicated by USFDABiocon Biologics' drug substance facility in Bengaluru has been classified by the USFDA as voluntary action indicated after a cGMP inspecti...
- Biocon Biologics inks licence pact with Janssen for biosimilar productThe agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Bioco...
- Biocon Biologics gets eight observations from USFDA for Malaysia insulin facilityThe US drug regulator issued 6 observations for drug substance, drug product units and quality Control laboratories and 2 observations for ...
- Biocon case: CBI files charge sheet against 5The agency in its charge sheet filed last week has annexed alleged incriminating WhatsApp texts exchanged between alleged conduit (a woman)...
- Allegations 'serious' & 'grave', says special court in Biocon Biologics caseThe special CBI court, in an 80-page order rejecting the bail pleas of all five accused in the case earlier this week, said: "The questions...
- Biocon Biologics bribery case: CBI yet to question Jt Drug Controller, other accusedA special court here had sent all the five accused, including a joint drug controller at Central Drugs Standard Control Organisation, to ju...
- Biocon Biologics denies bribery charge; says it follows due regulatory process for product approvalsThe CBI has arrested Joint Drugs Controller S Eswara Reddy, Associate Vice President of Biocon Biologics L Praveen Kumar and three others i...
- USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard revie...
- True North buys into Biocon Biologics, deal values firm at around $3.5 billionTrue North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...
- Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licenceThis additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its...
- Biocon gets EIR from USFDA for Bengaluru biologics unitBiopharma major Biocon reportedly received an Establishment Inspection Report (EIR) from US-FDA for its biologics drug product unit at Beng...
- Biocon teams up with Sandoz for next-gen BiosimilarsBiosimilars are identical copies of highly complex biologic drugs that are said to have the same efficacy.
- Biocon gets DCGI approval to market anti-psoriasis drug, Itolizumab"The company has received market authorisation from the DCGI for its novel biologic Itolizumab, for treatment of chronic plaque psoriasis,"...
Load More
